Our partnerships with leading medical researchers, engineers and manufacturers support endra’s commitment to bringing taeus® to market We benefit from each of these companies’ deep expertise. Francois michelon, ceo of endra life sciences inc., explains how endra is leading early detection of liver diseases and issues with existing tools’ diagnostic and accessibility properties. Members of the endra life sciences team will be attending the congress and can be reached at the following email to arrange a meeting Country * select one afghanistan åland islands albania algeria american samoa andorra angola anguilla antarctica antigua and barbuda argentina armenia aruba australia austria azerbaijan bahamas bahrain bangladesh barbados belarus belgium belize benin bermuda bhutan bolivia, plurinational state of bonaire, sint eustatius and saba bosnia and herzegovina botswana bouvet island brazil british. Liver disease is commonplace and largely undiagnosed
Thankfully, a simple tool is on the horizon Endra’s technology, taeus®, is designed to provide some of the capabilities of ct/mri, but at a fraction of the cost and at the point of care, simply by plugging in to a conventional ultrasound machine. Lou basenese director anthony digiandomenico director michael harsh director alexander tokman ceo & director
OPEN
